valsartan has been researched along with Cardiomegaly in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (14.29) | 18.2507 |
| 2000's | 14 (33.33) | 29.6817 |
| 2010's | 12 (28.57) | 24.3611 |
| 2020's | 10 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, Q; Li, G; Li, Y; Liu, T; Shao, S; Suo, Y; Wang, Y; Yang, Q; Yuan, M; Zhang, Y | 1 |
| Abdullah, DM; Alsemeh, AE; Khamis, T | 1 |
| Asghari, AA; Hosseini, SJ; Mahmoudabady, M; Mousavi Emadi, Z; Salmani, H | 1 |
| Ge, Q; Hu, Z; Liu, C; Pan, C; Ren, X; Yu, YH; Zhao, L | 1 |
| Chen, X; Du, F; Gao, Z; Hua, H; Jing, X; Li, S; Sun, G; Sun, J; Xiao, Y; Xu, W | 1 |
| Cai, SY; Fu, YL; Lin, Q; Peng, FH; Tao, L; Wang, Q; Zheng, NZ | 1 |
| Chen, SW; Ding, Y; Li, J; Li, WH; Liu, SW; Lu, XF; Peng, S; Qi, YD; Wei, Y; Wu, XY; Xu, J; Yuan, TY; Zhou, GQ | 1 |
| Andresen, H; Bendiksen, BA; Bergo, KK; Cataliotti, A; Christensen, G; Espe, EK; Hasic, A; Hauge-Iversen, IM; Hussain, RI; Nordén, ES; Sjaastad, I; Veras, I | 1 |
| Chen, Y; Wu, Y | 1 |
| Alfadda, AA; Alsalman, N; Bazighifan, A; Gul, R | 1 |
| Jing, W; Kashyap, ML; Khazaeli, M; Moradi, H; Nunes, A; Suematsu, Y; Vaziri, ND | 1 |
| Duran, SH; Jung, S; Newhard, DK; Winter, RL | 1 |
| Hamano, G; Moritani, T; Rakugi, H; Shimosato, T; Takami, Y; Takeshita, H; Yamamoto, K | 1 |
| Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Nakagawa, T; Ogawa, H; Sueta, D | 1 |
| Qin, X; Sheng, H; Yao, J; Zhu, J | 1 |
| Liu, GS | 1 |
| Gu, Y; Liu, XY; Wang, H; Wu, J; Zhang, MJ; Zhu, PF | 1 |
| He, XX; Liang, QS; Zhan, CY; Zhou, DX | 1 |
| Fu, L; Gao, Y; Han, Y; Li, Y; Ma, D; Shen, J; Wang, F; Wang, Y; Xie, R; Zhou, P | 1 |
| Barlera, S; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lucci, D; Maggioni, AP; Staszewsky, L; Tognoni, G | 1 |
| Dong, YF; Fukuda, M; Kaneko, T; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakagata, N; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E | 1 |
| Smit, MD; Van Gelder, IC | 1 |
| Chen, X; Dong, J; Jiang, L; Jiang, W; So, Y; Xin, H | 1 |
| Biala, A; Eriksson, O; Finckenberg, P; Kaheinen, P; Lapatto, R; Lempiäinen, J; Louhelainen, M; Luft, FC; Martonen, E; Mattila, I; Merasto, S; Mervaala, E; Muller, DN; Oresic, M | 1 |
| Ge, J; Gong, H; Komuro, I; Li, L; Lin, L; Wu, J; Zhou, N; Zou, Y | 1 |
| Chen, J; Huang, L; Le, X; Meng, J; Tang, Y; Wang, M; Wu, P; Yu, P | 1 |
| Biala, A; Finckenberg, P; Korpi, A; Levijoki, J; Loytainen, M; Martonen, E; Mervaala, E | 1 |
| Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM | 1 |
| Inagaki, K; Iwanaga, Y; Kihara, Y; Mochly-Rosen, D; Onozawa, Y; Sarai, N; Takenaka, H | 1 |
| Allen, TJ; Burrell, LM; Cao, Z; Cooper, ME; Davis, BJ; Lassila, M | 1 |
| Bedigian, MP; Lu, L; Robinson, AD; Sun, Y; Weber, KT; Zhang, J | 1 |
| Dechend, R; Feldman, DL; Fiebeler, A; Garrelds, IM; Gratze, P; Jan Danser, AH; Luft, FC; Meiners, S; Müller, DN; Pilz, B; Shagdarsuren, E; Webb, RL; Wellner, M | 1 |
| Chen, S; Huang, H; Li, R; Liu, P; Tang, F; Wang, P; Zhang, H | 1 |
| Cao, Z; Cooper, ME; Hulthén, UL; Johnston, CI; Rumble, JR | 1 |
| Hayashi, N; Inukai, T; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| Fujimura, Y; Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| Goa, KL; Markham, A | 1 |
| Balaev, VV; Drozdova, GA; Frolov, VA; Mustiatsa, VF; Rieger, P | 1 |
| De Gasparo, M; Fornes, P; Gervais, M; Giudicelli, JF; Richer, C | 1 |
| Basset, A; Blanc, J; Elghozi, JL | 1 |
| Akishita, M; Chen, R; de Gasparo, M; Horiuchi, M; Iwai, M; Nakagami, H; Suzuki, J; Wu, L | 1 |
| Chen, Y; Li, W; Liu, W; Sun, N; Yu, Y | 1 |
1 review(s) available for valsartan and Cardiomegaly
| Article | Year |
|---|---|
Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.
Topics: Antihypertensive Agents; Cardiomegaly; Humans; Hypertension; Receptors, Angiotensin; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 1997 |
2 trial(s) available for valsartan and Cardiomegaly
| Article | Year |
|---|---|
A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; Cardiomegaly; Creatinine; Dog Diseases; Dogs; Double-Blind Method; Drug Combinations; Electrolytes; Female; Male; Mitral Valve Insufficiency; Pilot Projects; Random Allocation; Tetrazoles; Valsartan | 2018 |
Valsartan for prevention of recurrent atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiomegaly; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double-Blind Method; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Tetrazoles; Valine; Valsartan | 2009 |
39 other study(ies) available for valsartan and Cardiomegaly
| Article | Year |
|---|---|
Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Diastole; Disease Models, Animal; Drug Combinations; Heart Failure; Mice; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction | 2022 |
Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Autophagy; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Epigenesis, Genetic; Fibrosis; Heart Failure; Hyperthyroidism; Male; MicroRNAs; Neprilysin; Rats; Rats, Wistar; Signal Transduction; Thyroxine; Valsartan | 2022 |
Cardiac hypertrophy and fibrosis were attenuated by olive leaf extract treatment in a rat model of diabetes.
Topics: Animals; Body Weight; Cardiomegaly; Diabetes Mellitus, Experimental; Fibrosis; Rats; Valsartan | 2022 |
LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Biphenyl Compounds; Cardiomegaly; Constriction, Pathologic; Disease Models, Animal; Drug Combinations; Fibrosis; Male; Mice; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan | 2020 |
Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
Topics: Administration, Oral; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomegaly; Chronic Disease; Disease Models, Animal; Dogs; Drug Combinations; Heart Failure; Myocardial Ischemia; Neprilysin; Protease Inhibitors; Rats, Sprague-Dawley; Recovery of Function; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
GJA1-20k attenuates Ang II-induced pathological cardiac hypertrophy by regulating gap junction formation and mitochondrial function.
Topics: Angiotensin II; Animals; Cardiomegaly; Connexin 43; Down-Regulation; Gap Junctions; Janus Kinase 2; Male; Membrane Potential, Mitochondrial; Mitochondria; Myocardium; Organelle Biogenesis; Rats, Inbred WKY; Reactive Oxygen Species; Signal Transduction; Tyrphostins; Valsartan | 2021 |
LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3/MnSOD Pathway.
Topics: Aminobutyrates; AMP-Activated Protein Kinases; Animals; Apoptosis; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Male; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirtuin 3; Superoxide Dismutase; Tetrazoles; Up-Regulation; Valsartan; Ventricular Remodeling | 2020 |
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Heart Failure; Rats; Rats, Sprague-Dawley; Stroke Volume; Valsartan | 2021 |
Reverse remodeling in a heart failure patient with cardiomegaly treated with sacubitril/valsartan: a case report.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Heart Failure; Humans; Percutaneous Coronary Intervention; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Comparative beneficial effects of nebivolol and nebivolol/valsartan combination against mitochondrial dysfunction in angiotensin II-induced pathology in H9c2 cardiomyoblasts.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiomegaly; Cell Culture Techniques; Drug Combinations; Heart; Hypertension; Inflammation; Mechanistic Target of Rapamycin Complex 1; Mitochondria; Myoblasts, Cardiac; Myocardium; Nebivolol; Organelle Biogenesis; Oxidative Stress; Rats; Reactive Oxygen Species; Valsartan | 2021 |
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Disease Models, Animal; Drug Combinations; Fibrosis; Heart Failure; Male; Neprilysin; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Effects of Low-Dose Sacubitril/Valsartan on Different Stages of Cardiac Hypertrophy in Salt-Loaded Hypertensive Rats.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Disease Models, Animal; Drug Combinations; Gene Expression Regulation; Kidney; Male; Neprilysin; Protease Inhibitors; Pulmonary Edema; Rats, Inbred SHR; Sodium Chloride, Dietary; Tetrazoles; Valsartan | 2019 |
LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Circadian Rhythm; Cyclic GMP; Drug Combinations; Drug Evaluation, Preclinical; Endothelium, Vascular; Fibrosis; Heart; Hypertension; Inflammation; Male; Myocardium; Neprilysin; Oxidative Stress; Random Allocation; Rats, Inbred SHR; Sodium, Dietary; Tetrazoles; Valsartan; Vascular Remodeling | 2015 |
Dyrk1A-ASF-CaMKIIδ Signaling Is Involved in Valsartan Inhibition of Cardiac Hypertrophy in Renovascular Hypertensive Rats.
Topics: Alternative Splicing; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Dyrk Kinases; Echocardiography; Hypertension; Male; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Valsartan | 2016 |
Dyrk1A-ASF-CaMKIIδ Signaling: New Mechanistic Insight Involved in Valsartan Inhibition of Cardiac Hypertrophy.
Topics: Cardiomegaly; Humans; Myocytes, Cardiac; Signal Transduction; Valsartan | 2016 |
Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling.
Topics: Animals; Cardio-Renal Syndrome; Cardiomegaly; Disease Models, Animal; Down-Regulation; Echocardiography; Galectin 3; Glomerular Filtration Rate; Heart; Heart Failure; Kidney; Male; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Signal Transduction; Valsartan | 2016 |
[Changes of c-fos, c-jun mRNA expressions in cardiomyocyte hypertrophy induced by angiotensin II and effects of tanshinone II A].
Topics: Abietanes; Angiotensin II; Animals; Cardiomegaly; Gene Expression Regulation; Genes, fos; Genes, jun; Myocytes, Cardiac; Phenanthrenes; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2008 |
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Cardiomegaly; Cyclic AMP Response Element Modulator; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 3; Gene Expression Regulation; Heart; Heart Failure; Myocardial Infarction; Myocardium; Rats; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2009 |
Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Cardiovascular System; Drug Synergism; Drug Therapy, Combination; Fumarates; Gene Expression; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Nitric Oxide Synthase Type III; Receptor, Angiotensin, Type 1; Renin; RNA, Messenger; Superoxides; Tetrazoles; Tunica Intima; Valine; Valsartan | 2009 |
Valsartan and recurrent atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiomegaly; Drug Administration Schedule; Humans; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2009 |
[Intermedin (IMD) gene expression in hypertrophic cardiac myocyte of renal vascular hypertension rats and the intervention of Valsartan, Amlodipine and Enalapril in the expression].
Topics: Adrenomedullin; Amlodipine; Animals; Antihypertensive Agents; Cardiomegaly; Enalapril; Hypertension, Renovascular; Male; Myocardium; Neuropeptides; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2009 |
Metabolomics in angiotensin II-induced cardiac hypertrophy.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Biomarkers; Cardiomegaly; Disease Models, Animal; Fatty Acids; Female; Humans; Hypoxanthine; Linoleic Acids; Male; Metabolomics; Mitochondria, Heart; Oxidative Stress; Probability; Random Allocation; Rats; Rats, Sprague-Dawley; Reference Values; Sirtuin 1; Survival Rate; Tetrazoles; Valine; Valsartan | 2010 |
Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrial Natriuretic Factor; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Echocardiography; Gene Expression; Hemodynamics; Imidazoles; Losartan; Male; Mice; Myocardium; Reverse Transcriptase Polymerase Chain Reaction; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Antioxidant and cardioprotective effects of Danshensu (3-(3, 4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Arrhythmias, Cardiac; Cardiomegaly; Cardiotonic Agents; Connexins; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Electrocardiography; Hemodynamics; Isoproterenol; Lactates; Male; Phytotherapy; Rats; Rats, Sprague-Dawley; Salvia miltiorrhiza; Tetrazoles; Valine; Valsartan | 2011 |
Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Diet, Sodium-Restricted; Echocardiography; Heart; Heart Failure; Heart Rate; Hydrazones; Hypertension; Kidney; Male; Myocytes, Cardiac; Pyridazines; Rats; Rats, Inbred Dahl; RNA, Messenger; Simendan; Sodium Chloride, Dietary; Sodium, Dietary; Tetrazoles; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2011 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan | 2013 |
Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Progression; Echocardiography; Enzyme Activation; Heart Failure; Hypertension; Male; Myocardium; Organ Size; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-epsilon; Protein Transport; Rats; Rats, Inbred Dahl; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2002 |
Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Topics: Alanine; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Captopril; Cardiomegaly; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Enzyme Inhibitors; Hypertension; Hypertrophy; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2003 |
Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Heart; In Situ Hybridization; Infusions, Parenteral; Male; Myocardium; Nephrectomy; NF-kappa B; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2004 |
Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetically Modified; Blood Pressure; Cardiomegaly; Dose-Response Relationship, Drug; Echocardiography; Fumarates; Humans; Hypertension; Kidney; Rats; Rats, Sprague-Dawley; Renin; Tetrazoles; Valine; Valsartan | 2005 |
Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Ventricles; Hypertension, Renovascular; Ligation; Male; Malondialdehyde; Membrane Glycoproteins; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Rats; Rats, Sprague-Dawley; Renal Artery; Superoxides; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2007 |
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Capillary Permeability; Cardiomegaly; Coloring Agents; Coronary Vessels; Diabetes Mellitus, Experimental; Dihydropyridines; Evans Blue; Hypertension; Hypertrophy; Kidney; Male; Mesenteric Arteries; Ramipril; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Serum Albumin; Tetrazoles; Valine; Valsartan | 1996 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Cardiomegaly; Cerebrovascular Disorders; Enalapril; Heart Rate; Hypertension; Male; Mesentery; Muscle Contraction; Organ Size; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Enalapril; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Organ Size; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1997 |
[Myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of formation of angiotensin II and its interaction with specific receptors].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiomegaly; Hypertension, Renovascular; Hypertrophy, Left Ventricular; Male; Myocardium; Rabbits; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 1999 |
Valsartan and coronary haemodynamics in early post-myocardial infarction in rats.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Body Weight; Cardiomegaly; Coronary Vessels; Dipyridamole; Dose-Response Relationship, Drug; Fibrosis; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 1999 |
[Contribution of the renin-angiotensin system to blood pressure variability in hyperthyroid rats].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiomegaly; Chronic Disease; Disease Models, Animal; Fever; Fourier Analysis; Heart Rate; Hypertension; Hyperthyroidism; Injections, Intraperitoneal; Male; Rats; Rats, Wistar; Renin; Renin-Angiotensin System; Signal Processing, Computer-Assisted; Tachycardia; Tetrazoles; Thyroid Hormones; Thyrotoxicosis; Thyroxine; Valine; Valsartan; Weight Loss | 2000 |
Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiomegaly; Coronary Vessels; Male; Mice; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2002 |
Influence of Valsartan on myocardial apoptosis in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Apoptosis; Cardiomegaly; Hypertension; Myocardium; Rats; Rats, Inbred SHR; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2002 |